New York-based Bristol-Myers has agreed to a deal with Japan’s Ono Pharmaceutical Co. for expanded rights to develop a potential cancer treatment. The companies also will develop and sell the rheumatoid arthritis treatment Orencia in Japan. The treatment is still in testing on several forms of cancer and aims to allow the immune system to work against tumor cells.
© Copyright 2011 Globe Newspaper Company.
